



Model List of Essential Medicines



Abacavir [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Abacavir + dolutegravir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Abacavir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Abacavir + lamivudine + lopinavir + ritonavir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Atazanavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Atazanavir + ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Darunavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Didanosine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Dolutegravir [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Dolutegravir + lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Efavirenz [General information](#)

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Solid: 600 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Efavirenz + emtricitabine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Efavirenz + lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [efavirenz + emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine + rilpivirine + tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine + rilpivirine + tenofovir disoproxil fumarate [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) [Contact with or exposure to human immunodeficiency virus](#)

☐

Emtricitabine + tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

☐

Indinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 400 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

☐

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim [General information](#)

Section

Medicines for prevention of HIV-related opportunistic infections

- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

[Other specified prophylactic measures](#)

☐

Lamivudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

☐

Lamivudine + nevirapine + zidovudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

☐

Lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Contact with or exposure to human immunodeficiency virus](#)

☐

Lamivudine + zidovudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Lopinavir + ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Nelfinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 250 mg (as mesilate)
- Oral > Other: 50 mg per g oral powder

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Nevirapine [General information](#)

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Raltegravir [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Saquinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 200 mg; 500 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Stavudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 5 mg per 5 mL powder for oral solution
- Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Tenofovir disoproxil fumarate [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) [Contact with or exposure to human immunodeficiency virus](#)



Zidovudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > tablet: 300 mg
- Oral > Solid > capsule: 250 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)